NOVAVAX INC (NVAX) Stock Price, Forecast & Analysis
USA - NASDAQ:NVAX - US6700024010 - Common Stock
NVAX Key Statistics, Chart & Performance
The current stock price of NVAX is 8.4 USD. In the past month the price decreased by -11.21%. In the past year, price decreased by -10.16%.
NVAX Latest News, Press Relases and Analysis
NVAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About NVAX
Company Profile
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Company Info
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND 20878 US
CEO: Stanley C. Erck
Employees: 952
Phone: 12402682000
NOVAVAX INC / NVAX FAQ
Can you describe the business of NOVAVAX INC?
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Can you provide the latest stock price for NOVAVAX INC?
The current stock price of NVAX is 8.4 USD. The price decreased by -0.36% in the last trading session.
Does NOVAVAX INC pay dividends?
NVAX does not pay a dividend.
How is the ChartMill rating for NOVAVAX INC?
NVAX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the market cap for NOVAVAX INC?
NOVAVAX INC (NVAX) has a market capitalization of 1.36B USD. This makes NVAX a Small Cap stock.
Can you provide the upcoming earnings date for NOVAVAX INC?
NOVAVAX INC (NVAX) will report earnings on 2025-11-05.
Who owns NOVAVAX INC?
You can find the ownership structure of NOVAVAX INC (NVAX) on the Ownership tab.
NVAX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NVAX. When comparing the yearly performance of all stocks, NVAX turns out to be only a medium performer in the overall market: it outperformed 61.95% of all stocks.
NVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NVAX. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health.
NVAX Financial Highlights
Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of 1.96. The EPS increased by 171.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.2% | ||
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| Debt/Equity | 5.93 |
NVAX Forecast & Estimates
14 analysts have analysed NVAX and the average price target is 13.55 USD. This implies a price increase of 61.33% is expected in the next year compared to the current price of 8.4.
For the next year, analysts expect an EPS growth of 257.71% and a revenue growth 57.45% for NVAX